Holen Sie sich die Stockscreener-App
181.85
1.48%
-3.1899
Schlusskurs vom Vortag:
$185.04
Offen:
$183.15
24-Stunden-Volumen:
73,689
Relative Volume:
0.09
Marktkapitalisierung:
$10.71B
Einnahmen:
$551.35M
Nettoeinkommen (Verlust:
$-189.33M
KGV:
-55.25
EPS:
-3.2916
Netto-Cashflow:
$-35.09M
1W Leistung:
+1.54%
1M Leistung:
+1.26%
6M Leistung:
+72.33%
1J Leistung:
+100.52%
1-Tages-Spanne:
$180.70
$183.33
1-Wochen-Bereich:
$172.98
$185.35
52-Wochen-Spanne:
$73.16
$191.62
Glaukos Corp Stock (GKOS) Company Profile
Firmenname
Glaukos Corp
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
181.56 | 10.91B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
106.03 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.80 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
273.31 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.67 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.44 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corp Aktie (GKOS) Neueste Nachrichten
Is Glaukos Corp (GKOS) Overvalued After 4.3% Rally? GF Value Say - GuruFocus
Enterprise value to EBITDA forward of Glaukos Corp – LSX:A14VCK - TradingView
Precipio Inc. (PRPO) Peer Comparison – Compare with Others - Value Research
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Bruker Corporation (BRKR) Peer Comparison – Compare with Others - Value Research
Quidel Corporation (QDEL) Peer Comparison – Compare with Others - Value Research
Heska Corporation (HSKA) Peer Comparison – Compare with Others - Value Research
UFP Technologies Inc. (UFPT) Peer Comparison – Compare with Others - Value Research
Natus Medical Incorporated (NTUS) Peer Comparison – Compare with Others - Value Research
Repro Med Systems Inc. (KRMD) Peer Comparison – Compare with Others - Value Research
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Codex DNA Inc (DNAY) Peer Comparison – Compare with Others - Value Research
GlucoTrack Inc (GCTK) Peer Comparison – Compare with Others - Value Research
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - Value Research
IsoPlexis Corporation (ISO) Peer Comparison – Compare with Others - Value Research
Pulse Biosciences Inc (DE) (PLSE) Peer Comparison – Compare with Others - Value Research
Glaukos chief development officer sells $2.48m in shares By Investing.com - Investing.com Nigeria
Glaukos chief development officer sells $2.48m in shares - Investing.com
Haemonetics Corporation (HAE) Peer Comparison – Compare with Others - Value Research
Glaukos stock trades at $179 as investors weigh recent growth and valuation - AD HOC NEWS
ICU Medical Inc. (ICUI) Peer Comparison – Compare with Others - Value Research
Trinity Biotech plcADR Peer Comparison – Compare with Others - Value Research
Acutus Medical Inc (AFIB) Peer Comparison – Compare with Others - Value Research
SS Innovations International Inc. (SSII) Peer Comparison – Compare with Others - Value Research
Bioventus Inc. Class A (BVS) Peer Comparison – Compare with Others - Value Research
Omnicell Inc. ($0.001 par value) (OMCL) Peer Comparison – Compare with Others - valueresearchonline.com
MaxCyte Inc. (MXCT) Peer Comparison – Compare with Others - valueresearchonline.com
Repligen Corporation (RGEN) Peer Comparison – Compare with Others - Value Research
Glaukos Corp (GKOS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Glaukos (NYSE: GKOS) insider eyes multimillion-dollar stock sale - Stock Titan
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Aethlon Medical Inc. (AEMD) Peer Comparison – Compare with Others - Value Research
Vivos Therapeutics Inc. (VVOS) Peer Comparison – Compare with Others - Value Research
Dentsply Sirona Inc (XRAY) Peer Comparison – Compare with Others - Value Research
Myriad Genetics Inc. (MYGN) Peer Comparison – Compare with Others - Value Research
TransMedics Group Inc. (TMDX) Peer Comparison – Compare with Others - Value Research
Bionano Genomics Inc. (BNGO) Peer Comparison – Compare with Others - Value Research
Innovative Eyewear Inc (LUCYW) Peer Comparison – Compare with Others - Value Research
Glaukos Corp (GKOS) Peer Comparison – Compare with Others - Value Research
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today - Benzinga
Why Is Glaukos (NYSE:GKOS) in Focus After Record Quarterly Sales? - Kalkine Media
Zacks Research Issues Positive Estimate for Glaukos Earnings - MarketBeat
Glaukos (GKOS) Stock Looks Pricey On High Growth Expectations - Sahm
BlackRock Inc. Takes Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corp stock hits all-time high at 190.27 USD By Investing.com - Investing.com South Africa
Glaukos director Kliman sells $475,000 in shares - Investing.com
Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 2,500 Shares of Stock - MarketBeat
Glaukos (NYSE: GKOS) director sells shares after option exercise - Stock Titan
GKOS Stock Surges 67% Year to Date: What's Driving the Rally? - Yahoo Finance
Glaukos Corp stock hits all-time high at 190.27 USD - Investing.com
BTIG Research Boosts Glaukos (NYSE:GKOS) Price Target to $202.00 - MarketBeat
Finanzdaten der Glaukos Corp-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):